BioStock: Annexin's CEO: "The cancer area more than doubles the potential"

Annexin Pharmaceuticals' candidate ANXV is being developed as a new treatment for retinal vein occlusion, an eye disease that affects more than 16 million people globally. However, the candidate has also shown promising potential in cancer, among other indications, and the Stockholm-based company has recently stepped into the field. BioStock spoke with CEO Anders Haegerstrand to get his take on the potential for ANXV in cancer.

Read the interview with Annexin Pharmaceuticals at biostock.se:

https://www.biostock.se/en/2023/02/annexins-ceo-the-cancer-area-more-than-doubles-the-potential

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/